These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37062209)

  • 1. Local recurrence in primary localised resected gastrointestinal stromal tumours: A registry observational national cohort study including 912 patients.
    Bleckman RF; Roets E; IJzerman NS; Mohammadi M; Bonenkamp HJJ; Gelderblom H; Mathijssen RHJ; Steeghs N; Reyners AKL; van Etten B
    Eur J Cancer; 2023 Jun; 186():113-121. PubMed ID: 37062209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
    Barrios CH; Blackstein ME; Blay JY; Casali PG; Chacon M; Gu J; Kang YK; Nishida T; Purkayastha D; Woodman RC; Reichardt P
    Eur J Cancer; 2015 Nov; 51(16):2423-33. PubMed ID: 26248685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
    Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
    Farag S; van Coevorden F; Sneekes E; Grunhagen DJ; Reyners AKL; Boonstra PA; van der Graaf WT; Gelderblom HJ; Steeghs N
    Eur J Cancer; 2017 Nov; 86():318-325. PubMed ID: 29073582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study.
    Hohenberger P; Bonvalot S; van Coevorden F; Rutkowski P; Stoeckle E; Olungu C; Litiere S; Wardelmann E; Gronchi A; Casali P
    Eur J Cancer; 2019 Oct; 120():47-53. PubMed ID: 31479947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
    Tang J; Zhao R; Zheng X; Xu L; Wang Y; Feng L; Ren S; Wang P; Zhang M; Xu M
    Medicine (Baltimore); 2018 Jul; 97(29):e11400. PubMed ID: 30024511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
    Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
    Guerin A; Sasane M; Gauthier G; Keir CH; Zhdavana M; Wu EQ
    J Med Econ; 2015 Mar; 18(3):241-8. PubMed ID: 25422992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.
    Gold JS; Gönen M; Gutiérrez A; Broto JM; García-del-Muro X; Smyrk TC; Maki RG; Singer S; Brennan MF; Antonescu CR; Donohue JH; DeMatteo RP
    Lancet Oncol; 2009 Nov; 10(11):1045-52. PubMed ID: 19793678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
    Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
    Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST).
    Tang S; Yin Y; Shen C; Chen J; Yin X; Zhang B; Yao Y; Yang J; Chen Z
    World J Surg Oncol; 2017 Apr; 15(1):79. PubMed ID: 28399894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological Features and Outcomes of Gastrointestinal Stromal Tumours in Oman: A multi-centre study.
    Al-Maqrashi Z; Burney IA; Taqi KM; Al-Sawafi Y; Qureshi A; Lakhtakia R; Mehdi I; Al-Bahrani B; Kumar S; Al-Moundhri M
    Sultan Qaboos Univ Med J; 2021 May; 21(2):e237-e243. PubMed ID: 34221471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
    Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG).
    Duffaud F; Meeus P; Bertucci F; Delhorme JB; Stoeckle E; Isambert N; Bompas E; Gagniere J; Bouché O; Toulmonde M; Salas S; Blay JY; Bonvalot S;
    Eur J Surg Oncol; 2017 Jun; 43(6):1110-1116. PubMed ID: 28433494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
    JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
    Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study.
    Mohammadi M; IJzerman NS; Hohenberger P; Rutkowski P; Jones RL; Martin-Broto J; Gronchi A; Schöffski P; Vassos N; Farag S; Baia M; Oosten AW; Steeghs N; Desar IME; Reyners AKL; van Sandick JW; Bastiaannet E; Gelderblom H; Schrage Y
    Eur J Surg Oncol; 2021 Aug; 47(8):2173-2181. PubMed ID: 33895019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.